Deep molecular response to gilteritinib in CHRYSALIS trial
Deep molecular response to gilteritinib in CHRYSALIS trial
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL
Clinical potential of trastuzumab biosimilar CTP6
Updates in melanoma: Treating BRAF and brain metastases
Alectinib eclipses crizotinib for ALK positive lung cancer
Targeted sequencing in endocrine refractory breast cancer
Results from the APHINITY trial of two HER2 targeted agents with chemo
Nivolumab and ipilimumab for metastatic sarcoma
Dose escalation results of ceritinib and nivolumab for ALK NSCLC
Phase III results of olaparib for BRCA breast cancer
Tivantinib as second line therapy for high-MET HCC